Drug intelligence / Profile preview

SA-008

Development stage: Preclinical
Lead developer: Sanopeutics

Overview

SA-008 is an early-stage drug candidate being developed by Sanopeutics for the treatment of metabolic disorders. As of early 2026, the program is in the discovery or preclinical stage of development. Specific details regarding the drug's molecular target, mechanism of action, and modality (such as whether it is a small molecule or a biologic) have not been publicly disclosed by the company. The candidate is part of a broader pipeline at Sanopeutics focusing on metabolic, infectious, and oncological diseases.

Beyond the preview

Go deeper on SA-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA-008.

Explore the full profile